Premium
Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID‐19
Author(s) -
Munblit Daniel,
Bobkova Polina,
Spiridonova Ekaterina,
Shikhaleva Anastasia,
Gamirova Aysylu,
Blyuss Oleg,
Nekliudov Nikita,
Bugaeva Polina,
Andreeva Margarita,
DunnGalvin Audrey,
Comberiati Pasquale,
Apfelbacher Christian,
Genuneit Jon,
Avdeev Sergey,
Kapustina Valentina,
Guekht Alla,
Fomin Victor,
Svistunov Andrey A.,
Timashev Peter,
Subbot Vladislav S.,
Royuk Valery V.,
Drake Thomas M.,
Hanson Sarah Wulf,
Merson Laura,
Carson Gail,
Horby Peter,
Sigfrid Louise,
Scott Janet T.,
Semple Malcolm G.,
Warner John O.,
Vos Theo,
Olliaro Piero,
Glybochko Petr,
Butnaru Denis
Publication year - 2021
Publication title -
clinical and experimental allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 154
eISSN - 1365-2222
pISSN - 0954-7894
DOI - 10.1111/cea.13997
Subject(s) - medicine , incidence (geometry) , asthma , covid-19 , pediatrics , mood , telephone interview , disease , psychiatry , social science , physics , sociology , infectious disease (medical specialty) , optics
Background The long‐term sequalae of COVID‐19 remain poorly characterized. We assessed persistent symptoms in previously hospitalized patients with COVID‐19 and assessed potential risk factors. Methods Data were collected from patients discharged from 4 hospitals in Moscow, Russia between 8 April and 10 July 2020. Participants were interviewed via telephone using an ISARIC Long‐term Follow‐up Study questionnaire. Results 2,649 of 4755 (56%) discharged patients were successfully evaluated, at median 218 (IQR 200, 236) days post‐discharge. COVID‐19 diagnosis was clinical in 1291 and molecular in 1358. Most cases were mild, but 902 (34%) required supplemental oxygen and 68 (2.6%) needed ventilatory support. Median age was 56 years (IQR 46, 66) and 1,353 (51.1%) were women. Persistent symptoms were reported by 1247 (47.1%) participants, with fatigue (21.2%), shortness of breath (14.5%) and forgetfulness (9.1%) the most common symptoms and chronic fatigue (25%) and respiratory (17.2%) the most common symptom categories. Female sex was associated with any persistent symptom category OR 1.83 (95% CI 1.55 to 2.17) with association being strongest for dermatological (3.26, 2.36 to 4.57) symptoms. Asthma and chronic pulmonary disease were not associated with persistent symptoms overall, but asthma was associated with neurological (1.95, 1.25 to 2.98) and mood and behavioural changes (2.02, 1.24 to 3.18), and chronic pulmonary disease was associated with chronic fatigue (1.68, 1.21 to 2.32). Conclusions Almost half of adults admitted to hospital due to COVID‐19 reported persistent symptoms 6 to 8 months after discharge. Fatigue and respiratory symptoms were most common, and female sex was associated with persistent symptoms.